Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet …

There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular
subsets, characterised by a low to very low incidence in all populations. The majority of …

Receptor tyrosine kinases (RTKs) play an important role in a variety of cellular processes
including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK …

New drug discovery has been acknowledged as a complicated, expensive, time-consuming,
and challenging project. It has been estimated that around 12 years and 2.7 billion USD, on …

Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, including non–small cell lung cancer. However, the clinical …

Purpose Fusions involving the ALK gene are the predominant genetic lesion underlying
pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors …

Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues, and can occur
almost anywhere in the body. Their rarity, and the heterogeneity of subtype and location …

Background ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs).
We assessed the tolerability and activity of crizotinib in patients with NSCLC who were …